The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change

Journal of Market Access and Health Policy

Volumn 5, Issue 1, 2017, Pages

  Young, K E ^a   Soussi, I ^a   Toumi, M ^b  

^a CREATIV CEUTICAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

ability to pay; affordability; differential pricing; Europe; external reference pricing; orphan drugs; pricing; Rare diseases; relative costs; treatment cost

Indexed keywords

EID: 85165622592     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.1080/20016689.2017.1369817     Document Type: Article

References (42)

1. European Medicines Agency (EMA): orphan drugs and rare diseases at a glance. accessed 2016 Jul 13. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069805.pdf
2. NICE. Citizens Council Report Ultra Orphan Drugs. [accessed 2016 Jul 14. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885144/pdf/bcp0062-0264.pdf
3. Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orpanet J Rare Dis. 2012;7:1.
4. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
5. Toumi M, Rémuzat C, Vataire AL, et al. External reference pricing of medicinal products: simulation based considerations for crosscountry coordination. 2013 [accessed 2016 Jul. http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
6. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
7. Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & EURODIS. Paris (France): EURODIS; 2010.
8. Heemstra HE. Variations in access and use of orphan drugs among EU member states. Eur J Hosp Pharm Practice. 2010;15(4):25–11.
9. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173–179.
10. Gammie T, Lu CY, Babar ZUD. Acess to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002.
11. Young KE, Soussi I, Hemels M, et al. A comparative study of orphan drug prices in Europe. J Mark Access Health Policy. 2017;5(1):1297886.
12. Eurostat.Population change - Demographic balance and crude rates at national level. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_gind&lang=en accessed 2017 Apr 18
13. IHS PharmOnline International (POLI). accessed 2016 Jun. https://www.ihs.com/products/pharmaonline-international.html
14. Ameli. [accessed 2016 Jul. http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
15. The British National Formulary (BNF). cited 2016 Jul. https://www.medicinescomplete.com/mc/login.htm
16. Farmadati. cited 2016 Jul. Available from: http://www.farmadati.it/
17. The OECD Economic Outlook online database. cited 2016 Dec. Available from: http://stats.oecd.org/
18. IMF International Monetary Fund, World Economic Outlook October 2016. cited 2016 Dec. Available from: http://www.imf.org/external/pubs/ft/weo/2016/02/index.htm
19. World Bank Open Data. cited 2016 Dec. Available from: http://data.worldbank.org/
20. Eurostat online database. Available from: http://ec.europa.eu/eurostat/data/database cited 2016 Dec.
21. WHO. Child Growth Standards: weight for Age. cited 2016 Jul. Available from: http://www.who.int/childgrowth/standards/weight_for_age/en/
22. Jonsson B, Hofmarcher T, Lindgren P, et al. Comparator report on patient access to cancer medicines in Europe revisited. Lund: IHE. (IHE Report 2016:4).
23. Iyengar S, TayTeo K, Vogler S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
24. Jakovljevic M, Lazarevic M, Milovanovic O, et al. The new and old Europe: East-West split in pharmaceutical spending. Front Pharmacol. 2016;7:18.
25. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. European Commission-European Economy. Economic papers 461. [updated 2012 Sep]. Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
26. OECD Purchasing Power Parities - Frequently Asked Questions (FAQs). cited 2017 Apr. Available from: http://www.oecd.org/std/prices-ppp/purchasingpowerparities-frequentlyaskedquestionsfaqs.htm
27. Vogler S, Lepuschütz L, Schneider P, et al. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. European Commission, DirectorateGeneral for Health and Food Safety Ed. Brussels: Publications Office of the European Union; 2015. Available from: https://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/pharmaproductpricing_frep_en.pdf
28. Remuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3. DOI:10.3402/jmahp.v3.27675
29. Espín J, Rovira J, Calleja A, et al. How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe? WHO Policy Brief; 2016. Available from: https://www.eu2017.mt/Documents/Programmes/PB21.pdf
30. NineOClock. Romania and Bulgaria, agreement on the patients’ access to medicines. Nov 2016. Available from: http://www.nineoclock.ro/romania-and-bulgaria-agreement-on-the-patients-access-to-medicines/
31. Visegrad Group. Bulletin: informal meeting of V4, Croatian and Lithuanian ministers of health, March 3, Warsaw. Jul 2017. Available from: http://www.visegradgroup.eu/visegrad-bulletin-5-2
32. Van Bael and Bellis. Beneluxa Cooperation for Medicines - Belgium and The Netherlands Jointly Decide not to Reimburse Cystic Fibrosis Medicine of Vertex. May 2017. Available from: https://www.vbb.com/insights/corporate-commercial/corporate-commercial/beneluxa-cooperation-for-medicines-belgium-and-the-netherlands-jointly-decide-not-to-reimburse-cystic-fibrosis-medicine-of-vertex
33. Michalopoulos S Southern EU states present unified front in drug talks. May 2017. Available from: https://www.euractiv.com/section/health-consumers/news/southern-eu-states-present-unified-front-in-drug-talks/
34. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(1):23–29.
35. De Cock J. Differential pricing of medicines in Europe: implications for access, innovation, and affordability. ISPOR 19th Annual European Congress Plenary Session; 2016 Oct; Vienna, Austria. Available from: https://www.ispor.org/Event/ReleasedPresentations/2016Vienna
36. Vogler S. Differential pricing of medicines in Europe. ISPOR 19th Annual European Congress Plenary Session; 2016 Oct; Vienna, Austria. Availabe from: https://www.ispor.org/Event/ReleasedPresentations/2016Vienna
37. Kanavos P. Differential pricing of medicines in Europe: implications for access, innovation, and affordability. ISPOR 19th Annual European Congress Plenary Session; 2016 Oct; Vienna, Austria. Available from: https://www.ispor.org/Event/ReleasedPresentations/2016Vienna
38. Towse A, Pistollato M, Mestre-Ferrandiz J, et al. European union pharmaceutical markets: a case for differential pricing? Int J Econ Business. 2015;22(2):263–275.
39. Remuzat C, Tavella F, Toumi M. Differential pricing for pharmaceuticals: overview of a widely debated pricing concept and key challenges. ISPOR 18th Annual European Congress; 2015 Nov; Milan, Italy. Available from: https://www.ispor.org/research_pdfs/51/pdffiles/PHP71.pdf
40. Yadav P. Differential pricing for pharmaceuticals. Study conducted for the U.K. Department for International Development; Zaragoza 2010.
41. Watal J. (WTO Secretariat). Workshop on differential pricing and financing of essential drugs. WHO-WTO Secretariat Workshop of 8–11 April 2001. Høsbjør, Norway.
42. Garau M, Towse A, Danzon P. Pharmaceutical pricing in Europe: is differential pricing a win-win solution?. Office Health Econ. 2011. Occasional paper 11/01 [Updated 11 February 2011]. Available from: https://www.ohe.org/publications/pharmaceutical-pricing-europe-differential-pricing-win-win-solution#